ベータサラセミア検査市場：検査タイプ、エンドユーザー、技術別-2025-2030年の世界予測

ベータサラセミア検査市場は、2023年に4億4,683万米ドルと評価され、2024年には4億7,847万米ドルに達すると予測され、CAGR 8.37％で成長し、2030年には7億8,435万米ドルに達すると予測されています。

ベータサラセミア検査は、遺伝性疾患であるため、遺伝子および出生前検査市場において重要なセグメントです。これは、ヘモグロビン産生の減少を特徴とする血液疾患であるβサラセミアを診断するための遺伝子スクリーニングを含みます。この検査は、特に地中海沿岸、中東、東南アジア地域など、この疾患の有病率が高い集団において不可欠であり、早期診断と疾患のより良い管理を助けるからです。ベータサラセミア検査の用途は、潜在的な遺伝子保因者の出生前検査、新生児スクリーニング、症状のある人の確定診断に及ぶ。最終用途は主に病院、診断研究所、専門クリニックです。

ベータサラセミア検査市場は、遺伝性疾患に対する意識の高まり、次世代シーケンサーのような遺伝子検査技術の進歩、遺伝性疾患のスクリーニングを促進するヘルスケア政策の支援といった成長要因の影響を受けています。さらに、より正確で、より迅速で、費用対効果の高い検査ソリューションを開発するための継続的な研究開発活動や戦略的提携が大きな機会をもたらしています。例えば、CRISPR-Cas9技術の活用は検査能力を向上させ、事業拡大の有望な領域に関するビジネスインサイトを提供する可能性があります。しかし、新興国では高度な診断検査へのアクセスが限られていることや、遺伝子検査プロトコルに関する規制の厳しさといった課題に直面しており、市場全体の成長可能性に影響を与えています。

自動化とデータ分析におけるAIの統合による検査精度の向上とコスト削減には、イノベーションの機会が豊富にあります。包括的な遺伝子パネルの開発のための研究機関との共同研究や提携も、市場の地位を高める可能性があります。業界プレーヤーは、地理的拡大、特にサラセミア負担の高い未開拓の農村地域での拡大に注力すべきです。市場競合情勢は中程度であり、主に技術の進歩とヘルスケア支出の増加に牽引されています。コンプライアンスを確保し、検査へのアクセスを拡大しながらイノベーションを起こせる企業は、この分野の信頼性と成長の可能性を活用できると思われます。

市場力学：急速に進化するベータサラセミア検査市場の主要市場インサイトを公開

ベータサラセミア検査市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界のβサラセミア有病率の増加により、特殊な検査法に対する需要が高まっています。
  • βサラセミアの早期発見と管理に対する意識の高まりと政府の取り組み
  • 発展途上地域におけるヘルスケアインフラの拡大によるベータサラセミア検査へのアクセスの提供
• 市場抑制要因
  • 高度な診断技術に伴う高度な検査技術の高コスト
• 市場機会
  • βサラセミアスクリーニングの普及を可能にする費用対効果の高い検査法の開発
  • ベータサラセミア検査および管理を促進する社会的認知の高まりと政府の取り組み
  • ヘルスケアプロバイダーとバイオテクノロジー企業の提携によるβサラセミア検査の進歩
• 市場の課題
  • ベータサラセミア検査のための専門医療施設へのアクセスが農村部や過疎地では限られていること

ポーターの5つの力：ベータサラセミア検査市場をナビゲートする戦略ツール

ポーターのファイブフォース（5つの力）は、ベータサラセミア検査市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：ベータサラセミア検査市場における外部からの影響の把握

外部マクロ環境要因は、ベータサラセミア検査市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析ベータサラセミア検査市場における競合情勢の把握

ベータサラセミア検査市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスベータサラセミア検査市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、ベータサラセミア検査市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨ベータサラセミア検査市場における成功への道筋を描く

ベータサラセミア検査市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • ベータサラセミアの罹患率が世界中で増加し、専門的な検査方法の需要が高まっている
    • ベータサラセミアの早期発見と管理に対する意識の高まりと政府の取り組み
    • 開発途上地域におけるヘルスケアインフラの拡大により、ベータサラセミア検査へのアクセスが可能
  • 抑制要因
    • 高度な診断技術に関連する高度な検査技術の高コスト
  • 機会
    • ベータサラセミアスクリーニングの普及を可能にする費用対効果の高い検査方法の開発
    • 国民の意識の高まりとベータサラセミア検査と管理を促進する政府の取り組み
    • ヘルスケア提供者とバイオテクノロジー企業の協力によりベータサラセミア検査の進歩を促進
  • 課題
    • ベータサラセミア検査の農村地域や発展途上地域では専門ヘルスケア施設へのアクセスが限られている
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTLE分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 ベータサラセミア検査市場テストタイプ別

• キャリアスクリーニング
• 診断検査
  • 遺伝子検査
  • 血液検査
• 新生児スクリーニング
• 出生前検査
  • 侵襲的出生前検査
  • 非侵襲的出生前検査（NIPT）

第7章 ベータサラセミア検査市場：エンドユーザー別

• 診断検査室
• 病院
• 調査機関
• 専門クリニック

第8章 ベータサラセミア検査市場：技術別

• マイクロアレイ技術
• 次世代シーケンシング（NGS）
• PCR（ポリメラーゼ連鎖反応）

第9章 南北アメリカのベータサラセミア検査市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のベータサラセミア検査市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのベータサラセミア検査市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• 1. Abbott Laboratories
• 2. Agilent Technologies, Inc.
• 3. ARUP Laboratories
• 4. Asuragen, Inc.
• 5. Bio-Rad Laboratories, Inc.
• 6. Biocept, Inc.
• 7. bioMerieux SA
• 8. Cepheid
• 9. F. Hoffmann-La Roche Ltd.
• 10. GenMark Diagnostics
• 11. Illumina, Inc.
• 12. Immucor, Inc.
• 13. Luminex Corporation
• 14. PerkinElmer, Inc.
• 15. QIAGEN N.V.
• 16. Quest Diagnostics Incorporated
• 17. Siemens Healthineers AG
• 18. Sysmex Corporation
• 19. Thermo Fisher Scientific Inc.
• 20. Trinity Biotech

LIST OF FIGURES

• FIGURE 1. BETA THALASSEMIA TESTING MARKET RESEARCH PROCESS
• FIGURE 2. BETA THALASSEMIA TESTING MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES BETA THALASSEMIA TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES BETA THALASSEMIA TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. BETA THALASSEMIA TESTING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. BETA THALASSEMIA TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. BETA THALASSEMIA TESTING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. BETA THALASSEMIA TESTING MARKET DYNAMICS
• TABLE 7. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY CARRIER SCREENING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY HEMATOLOGICAL TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY NEWBORN SCREENING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY INVASIVE PRENATAL TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY NON-INVASIVE PRENATAL TESTING (NIPT), BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY MICROARRAY TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL BETA THALASSEMIA TESTING MARKET SIZE, BY PCR (POLYMERASE CHAIN REACTION), BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 32. AMERICAS BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
• TABLE 36. ARGENTINA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 37. ARGENTINA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
• TABLE 41. BRAZIL BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 42. BRAZIL BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 43. CANADA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 44. CANADA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
• TABLE 45. CANADA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
• TABLE 46. CANADA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 47. CANADA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 48. MEXICO BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 49. MEXICO BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
• TABLE 51. MEXICO BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 52. MEXICO BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 53. UNITED STATES BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 57. UNITED STATES BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 58. UNITED STATES BETA THALASSEMIA TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 59. ASIA-PACIFIC BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 63. ASIA-PACIFIC BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 64. ASIA-PACIFIC BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 65. AUSTRALIA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 66. AUSTRALIA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
• TABLE 68. AUSTRALIA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 69. AUSTRALIA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 70. CHINA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 71. CHINA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
• TABLE 72. CHINA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
• TABLE 73. CHINA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 74. CHINA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 75. INDIA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 76. INDIA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
• TABLE 77. INDIA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
• TABLE 78. INDIA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 79. INDIA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 80. INDONESIA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 81. INDONESIA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
• TABLE 82. INDONESIA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
• TABLE 83. INDONESIA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 84. INDONESIA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 85. JAPAN BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 86. JAPAN BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
• TABLE 87. JAPAN BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
• TABLE 88. JAPAN BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 89. JAPAN BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 90. MALAYSIA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 91. MALAYSIA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
• TABLE 92. MALAYSIA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
• TABLE 93. MALAYSIA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 94. MALAYSIA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 95. PHILIPPINES BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 96. PHILIPPINES BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
• TABLE 97. PHILIPPINES BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
• TABLE 98. PHILIPPINES BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 99. PHILIPPINES BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 100. SINGAPORE BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 101. SINGAPORE BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
• TABLE 102. SINGAPORE BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
• TABLE 103. SINGAPORE BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 104. SINGAPORE BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 105. SOUTH KOREA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 106. SOUTH KOREA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
• TABLE 107. SOUTH KOREA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
• TABLE 108. SOUTH KOREA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 109. SOUTH KOREA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 110. TAIWAN BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 111. TAIWAN BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
• TABLE 112. TAIWAN BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
• TABLE 113. TAIWAN BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 114. TAIWAN BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 115. THAILAND BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 116. THAILAND BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
• TABLE 117. THAILAND BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
• TABLE 118. THAILAND BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 119. THAILAND BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 120. VIETNAM BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 121. VIETNAM BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
• TABLE 122. VIETNAM BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
• TABLE 123. VIETNAM BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 124. VIETNAM BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 125. EUROPE, MIDDLE EAST & AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 126. EUROPE, MIDDLE EAST & AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 129. EUROPE, MIDDLE EAST & AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 130. EUROPE, MIDDLE EAST & AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 131. DENMARK BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 132. DENMARK BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
• TABLE 133. DENMARK BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
• TABLE 134. DENMARK BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 135. DENMARK BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 136. EGYPT BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 137. EGYPT BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
• TABLE 138. EGYPT BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
• TABLE 139. EGYPT BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 140. EGYPT BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 141. FINLAND BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 142. FINLAND BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
• TABLE 143. FINLAND BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
• TABLE 144. FINLAND BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 145. FINLAND BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 146. FRANCE BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 147. FRANCE BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
• TABLE 148. FRANCE BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
• TABLE 149. FRANCE BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 150. FRANCE BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 151. GERMANY BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 152. GERMANY BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
• TABLE 153. GERMANY BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
• TABLE 154. GERMANY BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 155. GERMANY BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 156. ISRAEL BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 157. ISRAEL BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
• TABLE 158. ISRAEL BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
• TABLE 159. ISRAEL BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 160. ISRAEL BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 161. ITALY BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 162. ITALY BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
• TABLE 163. ITALY BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
• TABLE 164. ITALY BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 165. ITALY BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 166. NETHERLANDS BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 167. NETHERLANDS BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
• TABLE 168. NETHERLANDS BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
• TABLE 169. NETHERLANDS BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 170. NETHERLANDS BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 171. NIGERIA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 172. NIGERIA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
• TABLE 173. NIGERIA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
• TABLE 174. NIGERIA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 175. NIGERIA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 176. NORWAY BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 177. NORWAY BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
• TABLE 178. NORWAY BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
• TABLE 179. NORWAY BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 180. NORWAY BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 181. POLAND BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 182. POLAND BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
• TABLE 183. POLAND BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
• TABLE 184. POLAND BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 185. POLAND BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 186. QATAR BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 187. QATAR BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
• TABLE 188. QATAR BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
• TABLE 189. QATAR BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 190. QATAR BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 191. RUSSIA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 192. RUSSIA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
• TABLE 193. RUSSIA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
• TABLE 194. RUSSIA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 195. RUSSIA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 196. SAUDI ARABIA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 197. SAUDI ARABIA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
• TABLE 198. SAUDI ARABIA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
• TABLE 199. SAUDI ARABIA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 200. SAUDI ARABIA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 201. SOUTH AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH AFRICA BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 206. SPAIN BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 207. SPAIN BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
• TABLE 208. SPAIN BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
• TABLE 209. SPAIN BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 210. SPAIN BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 211. SWEDEN BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 212. SWEDEN BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
• TABLE 213. SWEDEN BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
• TABLE 214. SWEDEN BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 215. SWEDEN BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 216. SWITZERLAND BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 217. SWITZERLAND BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
• TABLE 218. SWITZERLAND BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
• TABLE 219. SWITZERLAND BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 220. SWITZERLAND BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 221. TURKEY BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 222. TURKEY BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
• TABLE 223. TURKEY BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
• TABLE 224. TURKEY BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 225. TURKEY BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 226. UNITED ARAB EMIRATES BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 227. UNITED ARAB EMIRATES BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
• TABLE 228. UNITED ARAB EMIRATES BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
• TABLE 229. UNITED ARAB EMIRATES BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 230. UNITED ARAB EMIRATES BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 231. UNITED KINGDOM BETA THALASSEMIA TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 232. UNITED KINGDOM BETA THALASSEMIA TESTING MARKET SIZE, BY DIAGNOSTIC TESTING, 2018-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM BETA THALASSEMIA TESTING MARKET SIZE, BY PRENATAL TESTING, 2018-2030 (USD MILLION)
• TABLE 234. UNITED KINGDOM BETA THALASSEMIA TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 235. UNITED KINGDOM BETA THALASSEMIA TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 236. BETA THALASSEMIA TESTING MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 237. BETA THALASSEMIA TESTING MARKET, FPNV POSITIONING MATRIX, 2023

The Beta Thalassemia Testing Market was valued at USD 446.83 million in 2023, expected to reach USD 478.47 million in 2024, and is projected to grow at a CAGR of 8.37%, to USD 784.35 million by 2030.

Beta Thalassemia testing is a critical segment within the genetic and prenatal testing market due to the hereditary nature of the disorder. It involves genetic screening to diagnose beta thalassemia, a blood disorder characterized by reduced hemoglobin production. This testing is essential in populations with a high prevalence of the disease, particularly in Mediterranean, Middle Eastern, and Southeast Asian regions, as it aids early diagnosis and better management of the disorder. Applications of beta thalassemia testing span prenatal testing for potential gene carriers, newborn screenings, and confirmatory diagnostics for symptomatic individuals. End-use scope majorly involves hospitals, diagnostic laboratories, and specialized clinics.

The market for beta thalassemia testing is influenced by growth factors such as increased awareness regarding genetic diseases, advancements in genetic testing technologies like next-gen sequencing, and supportive healthcare policies promoting genetic disorder screening. Moreover, ongoing research and development activities and strategic collaborations for developing more precise, faster, and cost-effective testing solutions present significant opportunities. For instance, leveraging CRISPR-Cas9 technology could enhance testing capabilities, offering business insights into promising areas for expansion. However, the market faces challenges like limited accessibility to advanced diagnostic tests in emerging economies and regulatory stringencies concerning genetic testing protocols, impacting overall growth potential.

Innovation opportunities abound in improving testing accuracy and reducing costs through automation and integration of AI in data analysis. Collaborations and partnerships with research institutions for developing comprehensive genetic panels can also enhance market standing. Industry players should focus on expanding geographically, especially in untapped rural regions with a high thalassemia burden. The beta thalassemia testing market presents a moderately competitive landscape, primarily driven by technological advancements and increasing healthcare expenditure. Companies that can innovate while ensuring compliance and expanding access to testing will likely capitalize on the sector's credibility and growth potential.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Beta Thalassemia Testing Market

The Beta Thalassemia Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of beta thalassemia worldwide driving demand for specialized testing methods
  • Rising awareness and government initiatives for early detection and management of beta thalassemia
  • Expansion of healthcare infrastructure in developing regions providing access to beta thalassemia testing
• Market Restraints
  • High costs of advanced testing technologies associated with advanced diagnostic technologies
• Market Opportunities
  • Development of cost-effective testing methods enabling widespread adoption of beta thalassemia screening
  • Rising public awareness and government initiatives promoting beta thalassemia testing and management
  • Collaborations between healthcare providers and biotech firms facilitating beta thalassemia test advancements
• Market Challenges
  • Limited access to specialized healthcare facilities in rural and underdeveloped regions for beta thalassemia testing

Porter's Five Forces: A Strategic Tool for Navigating the Beta Thalassemia Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Beta Thalassemia Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Beta Thalassemia Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Beta Thalassemia Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Beta Thalassemia Testing Market

A detailed market share analysis in the Beta Thalassemia Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Beta Thalassemia Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Beta Thalassemia Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Beta Thalassemia Testing Market

A strategic analysis of the Beta Thalassemia Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Beta Thalassemia Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., ARUP Laboratories, Asuragen, Inc., Bio-Rad Laboratories, Inc., Biocept, Inc., bioMerieux SA, Cepheid, F. Hoffmann-La Roche Ltd., GenMark Diagnostics, Illumina, Inc., Immucor, Inc., Luminex Corporation, PerkinElmer, Inc., QIAGEN N.V., Quest Diagnostics Incorporated, Siemens Healthineers AG, Sysmex Corporation, Thermo Fisher Scientific Inc., and Trinity Biotech.

Market Segmentation & Coverage

This research report categorizes the Beta Thalassemia Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Test Type, market is studied across Carrier Screening, Diagnostic Testing, Newborn Screening, and Prenatal Testing. The Diagnostic Testing is further studied across Genetic Testing and Hematological Testing. The Prenatal Testing is further studied across Invasive Prenatal Testing and Non-Invasive Prenatal Testing (NIPT).
• Based on End User, market is studied across Diagnostic Laboratories, Hospitals, Research Institutes, and Specialty Clinics.
• Based on Technology, market is studied across Microarray Technology, Next-Generation Sequencing (NGS), and PCR (Polymerase Chain Reaction).
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of beta thalassemia worldwide driving demand for specialized testing methods
    • 5.1.1.2. Rising awareness and government initiatives for early detection and management of beta thalassemia
    • 5.1.1.3. Expansion of healthcare infrastructure in developing regions providing access to beta thalassemia testing
  • 5.1.2. Restraints
    • 5.1.2.1. High costs of advanced testing technologies associated with advanced diagnostic technologies
  • 5.1.3. Opportunities
    • 5.1.3.1. Development of cost-effective testing methods enabling widespread adoption of beta thalassemia screening
    • 5.1.3.2. Rising public awareness and government initiatives promoting beta thalassemia testing and management
    • 5.1.3.3. Collaborations between healthcare providers and biotech firms facilitating beta thalassemia test advancements
  • 5.1.4. Challenges
    • 5.1.4.1. Limited access to specialized healthcare facilities in rural and underdeveloped regions for beta thalassemia testing
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Beta Thalassemia Testing Market, by Test Type

• 6.1. Introduction
• 6.2. Carrier Screening
• 6.3. Diagnostic Testing
  • 6.3.1. Genetic Testing
  • 6.3.2. Hematological Testing
• 6.4. Newborn Screening
• 6.5. Prenatal Testing
  • 6.5.1. Invasive Prenatal Testing
  • 6.5.2. Non-Invasive Prenatal Testing (NIPT)

7. Beta Thalassemia Testing Market, by End User

• 7.1. Introduction
• 7.2. Diagnostic Laboratories
• 7.3. Hospitals
• 7.4. Research Institutes
• 7.5. Specialty Clinics

8. Beta Thalassemia Testing Market, by Technology

• 8.1. Introduction
• 8.2. Microarray Technology
• 8.3. Next-Generation Sequencing (NGS)
• 8.4. PCR (Polymerase Chain Reaction)

9. Americas Beta Thalassemia Testing Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Beta Thalassemia Testing Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Beta Thalassemia Testing Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Agilent Technologies, Inc.
• 3. ARUP Laboratories
• 4. Asuragen, Inc.
• 5. Bio-Rad Laboratories, Inc.
• 6. Biocept, Inc.
• 7. bioMerieux SA
• 8. Cepheid
• 9. F. Hoffmann-La Roche Ltd.
• 10. GenMark Diagnostics
• 11. Illumina, Inc.
• 12. Immucor, Inc.
• 13. Luminex Corporation
• 14. PerkinElmer, Inc.
• 15. QIAGEN N.V.
• 16. Quest Diagnostics Incorporated
• 17. Siemens Healthineers AG
• 18. Sysmex Corporation
• 19. Thermo Fisher Scientific Inc.
• 20. Trinity Biotech